- Stocks
- Pharma & Healthcare
- Metropolis Healthcare
Metropolis Healthcare share price
NSE: METROPOLISPharma & HealthcareDiagnostics & Research
Metropolis Healthcare at a glance
Metropolis Healthcare (NSE: METROPOLIS) closed at ₹532.25 on 22 Oct 2026, down 0.03% on the day. With a market capitalisation of ₹11,035 Cr, it ranks 529th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 57.9× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has risen 9.2%. Its 52-week range is ₹412.25 (2 Apr 2026) to ₹609.05 (30 Jul 2026); the last close is 12.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹450 Cr (+16.6% year on year) and net profit ₹57 Cr (+25.7%), on a consolidated basis. Promoters held 48.86% of the company as of 30 Jun 2026; 1.18% of promoter shares were pledged.
Key numbers
- Market cap
- ₹11,035 CrRank 529 on NSE
- P/E (trailing)
- 57.9×
- Price to book
- 5.94×FY26
- EPS (TTM)
- ₹23.35to Q1 FY27
- ROE
- 12.6%FY26
- ROCE
- 16.2%FY26
- Debt to equity
- 0.01FY26
- Net profit margin
- 11.6%FY26
- Book value / share
- ₹72.98FY26
- 52-week high
- ₹609.0530 Jul 2026
- 52-week low
- ₹412.252 Apr 2026
- 1-year return
- +9.2%
- RSI (14-day)
- 44.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.03% | +1.8% | −11.1% | −6.5% | +9.2% |
Metropolis Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹350 Cr | ₹323 Cr | ₹345 Cr | ₹386 Cr | ₹429 Cr | ₹406 Cr | ₹425 Cr | ₹450 Cr |
| Revenue YoY | +13.4% | +10.9% | +4.3% | +23.2% | +22.7% | +25.8% | +23.0% | +16.6% |
| Net profit | ₹47 Cr | ₹31 Cr | ₹29 Cr | ₹45 Cr | ₹53 Cr | ₹42 Cr | ₹51 Cr | ₹57 Cr |
| Net profit YoY | +31.0% | +15.3% | −20.0% | +18.7% | +13.3% | +33.7% | +74.3% | +25.7% |
| Net margin | 13.4% | 9.7% | 8.5% | 11.7% | 12.3% | 10.4% | 12.0% | 12.6% |
| EPS | ₹9.08 | ₹6.12 | ₹5.69 | ₹8.70 | ₹10.17 | ₹7.99 | ₹2.46 | ₹2.73 |
Metropolis Healthcare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹998 Cr | ₹1,228 Cr | ₹1,148 Cr | ₹1,208 Cr | ₹1,331 Cr | — |
| Operating profit | ₹244 Cr | ₹277 Cr | ₹188 Cr | ₹175 Cr | ₹191 Cr | — |
| Net profit | ₹183 Cr | ₹215 Cr | ₹143 Cr | ₹128 Cr | ₹146 Cr | — |
| EPS (₹) | ₹36.00 | ₹42.00 | ₹28.00 | ₹25.00 | ₹28.00 | — |
| Cash from operations | ₹249 Cr | ₹253 Cr | ₹247 Cr | ₹264 Cr | ₹263 Cr | — |
| Total debt | ₹0 Cr | ₹159 Cr | ₹29 Cr | ₹0 Cr | ₹5 Cr | ₹0 Cr |
| Shareholders' equity | ₹707 Cr | ₹888 Cr | ₹988 Cr | ₹1,096 Cr | ₹1,331 Cr | ₹1,513 Cr |
Metropolis Healthcare shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 23 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 48.89% | 48.89% | 48.88% | 48.87% | 48.87% | 48.86% |
| Foreign institutions | 12.83% | 12.52% | 11.69% | 10.77% | 10.43% | 11.03% |
| Domestic institutions | 32.40% | 33.10% | 34.73% | 35.46% | 35.79% | 35.12% |
| Non-institutions | 5.88% | 5.49% | 4.71% | 4.91% | 4.91% | 4.99% |
| Promoter shares pledged | 1.18% | 1.18% | 1.18% | 1.18% | 1.18% | 1.18% |
Metropolis Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Metropolis Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,383 Cr | 66.8 | — |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,245 Cr | 43.9 | — |
| SUDEEPPHRMSudeep Pharma | ₹984.90 | +1.02% | — | ₹11,124 Cr | 66.2 | — |
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
Ask anything about Metropolis Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against METROPOLIS's own history. Try: “Why has METROPOLIS moved over the last three months?” · “Backtest a 50-day moving-average crossover on METROPOLIS over five years” · “Compare METROPOLIS with CORONA on margins and valuation”
Frequently asked questions about Metropolis Healthcare
What is the share price of Metropolis Healthcare today?
Metropolis Healthcare (NSE: METROPOLIS) last closed at ₹532.25 on 22 Oct 2026. Its 52-week high is ₹609.05 and its 52-week low is ₹412.25.
What is the market cap of Metropolis Healthcare?
Metropolis Healthcare's market capitalisation is ₹11,035 Cr (₹11,035 Cr) at the 22 Oct 2026 close, ranking 529th among the NSE companies Pivot tracks.
What is the P/E ratio of Metropolis Healthcare?
Metropolis Healthcare trades at a trailing P/E of 57.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.
What is the ROE and ROCE of Metropolis Healthcare?
Return on equity was 12.6% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).
Is Metropolis Healthcare a debt-free company?
Metropolis Healthcare is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.
What were Metropolis Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Metropolis Healthcare reported revenue of ₹450 Cr, +16.6% year on year, and net profit of ₹57 Cr, +25.7% year on year.
How has Metropolis Healthcare stock performed over the last year?
Metropolis Healthcare's share price has risen 9.2% over the past year, −6.5% over three months and −11.1% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Metropolis Healthcare?
As of 30 Jun 2026: promoters 48.86%, foreign institutions 11.03%, domestic institutions 35.12%, non-institutions 4.99%. 1.18% of promoter shares were pledged.
Who are Metropolis Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Metropolis Healthcare by market cap are CORONA Remedies, Rainbow Childrens Medicare, Sudeep Pharma, Akums Drugs and Pharmaceuticals, Park Medi World and Blue Jet Healthcare.
Is Metropolis Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Metropolis Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on METROPOLIS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text